2-(4-fluoro-2-nitrophenylthio)aniline | 322-73-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(4-fluoro-2-nitrophenylthio)aniline
• 英文别名: 2-(4-fluoro-2-nitro-phenylsulfanyl)-aniline；2-(4-Fluor-2-nitro-phenylmercapto)-anilin；2-(4-Fluoro-2-nitrophenyl)sulfanylaniline
• CAS: 322-73-6
• 化学式: C₁₂H₉FN₂O₂S
• 分子量: 264.28
• InChiKey: UQWUSLRRVOVDDY-UHFFFAOYSA-N

物化性质

• 沸点：
  386.3±42.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-fluoro-2-nitrophenylthio)aniline 在 sodium hydroxide 、 水 、 丙酮 作用下， 生成 3-氟-10H-吩噻嗪
  参考文献：
  名称：

  THE PREPARATION OF SOME FLUORO- AND TRIFLUOROMETHYL-PHENOTHIAZINES, AND SOME OBSERVATIONS REGARDING DETERMINATION OF THEIR STRUCTURE BY INFRARED SPECTROSCOPY¹

  摘要：

  DOI：

  10.1021/jo01128a018
• 作为产物：
  描述：

  2,5-二氟硝基苯 、 2-氨基苯硫醇 在 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以51%的产率得到2-(4-fluoro-2-nitrophenylthio)aniline
  参考文献：
  名称：

  Modulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors

  摘要：

  A forward chemical genetic approach was followed to discover new targets and lead compounds for Parkinson's disease (PD) treatment. By analysis of the cell protection produced by some small molecules, a diphenyl sulfide compound was revealed to be a new phosphodiesterase 7 (PDE7) inhibitor and identified as a new hit. This result allows us to confirm the utility of PDE7 inhibitors as a potential pharmacological treatment of PD. On the basis of these data, a diverse family of diphenyl sulfides has been developed and pharmacologically evaluated in the present work. Moreover, to gain insight into the safety of PDE7 inhibitors for human chronic treatment, we evaluated the new compounds in a surrogate emesis model, showing nonemetic effects.

  DOI：

  10.1021/jm501090m

文献信息

• Dibenzo[ <i>b</i> , <i>f</i> ][1,4,5]chalcogenadiazepine Photoswitches: Conversion of Excitation Energy into Ring Strain
  作者：Xin Shen、Cefei Zhang、Fengying Lan、Zhishan Su、Yuanqin Zheng、Tingting Zheng、Qin Xiong、Xinyu Xie、Guangxi Du、Xiaohu Zhao、Changwei Hu、Pengchi Deng、Zhipeng Yu

  DOI：10.1002/anie.202209441

  日期：2022.10.10

  Chalcogen-bridged seven-membered cyclic azobenzenes, dibenzo[b,f][1,4,5]chalcogenadiazepine (DBChD), exhibit distinct photo-switching characters with a high-energy E-configuration, especially for sulfur-bridged DBTD with an energy transduction efficiency of 21 % (η) under 445 nm laser activation. Introducing oligothiophene π-EDG on DBTD could further elevate the absorption λmax and coefficient ϵ, reaching

  硫属元素桥接的七元环状偶氮苯二苯并[ b , f ][1,4,5]硫属二氮杂卓 (DBChD) 具有高能 E 构型的独特光开关特性，特别是对于具有高能 E 构型的硫桥接 DBTD在 445 nm 激光激活下，能量转换效率为 21% (η)。在 DBTD 上引入低聚噻吩 π-EDG 可以进一步提高吸收 λ max和系数 ϵ，达到 η=29 %。
• THE PREPARATION OF SOME FLUORO- AND TRIFLUOROMETHYL-PHENOTHIAZINES, AND SOME OBSERVATIONS REGARDING DETERMINATION OF THEIR STRUCTURE BY INFRARED SPECTROSCOPY¹
  作者：ARTHUR ROE、WILLIAM F. LITTLE

  DOI：10.1021/jo01128a018

  日期：1955.11
• Modulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors
  作者：Ana M. García、José Brea、Jose A. Morales-García、Daniel I. Perez、Alejandro González、Sandra Alonso-Gil、Irene Gracia-Rubio、Clara Ros-Simó、Santiago Conde、María Isabel Cadavid、María Isabel Loza、Ana Perez-Castillo、Olga Valverde、Ana Martinez、Carmen Gil

  DOI：10.1021/jm501090m

  日期：2014.10.23

  A forward chemical genetic approach was followed to discover new targets and lead compounds for Parkinson's disease (PD) treatment. By analysis of the cell protection produced by some small molecules, a diphenyl sulfide compound was revealed to be a new phosphodiesterase 7 (PDE7) inhibitor and identified as a new hit. This result allows us to confirm the utility of PDE7 inhibitors as a potential pharmacological treatment of PD. On the basis of these data, a diverse family of diphenyl sulfides has been developed and pharmacologically evaluated in the present work. Moreover, to gain insight into the safety of PDE7 inhibitors for human chronic treatment, we evaluated the new compounds in a surrogate emesis model, showing nonemetic effects.